CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

CheckMate 649, un approfondimento sul follow-up a 4 anni

CheckMate 649 3-Year Follow-up: Nivolumab Plus Chemotherapy for Gastric and Esophageal Cancers

Checkmate 649 | Out now on Plenary Session Podcast feed

CheckMate 649: 1L nivo + chemotherapy improves OS

3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC

NIVO + chemo vs chemo as 1L treatment for advanced GC/GEJC/EAC: 4 year yr follow-up of CheckMate 649

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting

CheckMate 649: nivolumabe + quimioterapia demonstra benefício de SG e SLP

Understanding, Detecting, and Treating Gastroesophageal Junction Adenocarcinoma

The 2023 OncoAlert Colloquium (GI Oncology)

Part 2 - Nivolumab with chemotherapy in advanced previously untreated Gastric - Dr. Anant Ramaswamy

Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study

37b Switch Maintenance ARMANI Phase 3 Study: Earlier Second Line Therapy

Catalysts for Change in Gastric & GEJ Cancer

Cancer Topics - Immunotherapy Breakthroughs in Esophageal Cancers

Gastrointestinal Cancer CME Series: Gastroesophageal Cancer

Targeted Therapy and Immunotherapy for Gastroesophageal Cancer Guideline

Clinical Trials Updates for Gastric Cancer Patients Webinar